Clinical Trial Update: Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating asciminib versus best available therapy in chronic myeloid leukemia in chronic phase patients previously treated with two or more tyr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Asciminib (asciminib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Leukemia, Chronic Myelogenous | Phase 2 | Status: COMPLETED